Circulation Research · 1994 · 124 citations · 0 references
MedicinePharmacologyPhysiologyMolecular PharmacologyNeuropharmacologyPharmacodynamicsCerebrovascular PhysiologyHemodynamic PharmacologyIon Channel PharmacologyIon Channel PhysiologyPotassium Channel BiophysicsVasoactive MedicationsAdenosine Receptor SignalingCerebral Arteriolar FunctionCerebral Blood Flow EffectsCerebral HemodynamicsCerebral VasodilationPial VasculatureTopical ApplicationVasodilator Pharmacology
We tested the hypothesis that dilatation of cerebral arterioles during hypoxia is mediated by activation of ATP-sensitive K+ channels. The diameter of pial arterioles was measured through a closed cranial window in anesthetized rabbits. Topical application of aprikalim (10(-6) mol/L), a direct activator of ATP-sensitive K+ channels, dilated pial arterioles by 18 +/- 3% (mean +/- SEM). Glibenclamide (10(-6) mol/L), an inhibitor of ATP-sensitive K+ channels, virtually abolished aprikalim-induced vasodilatation. When arterial PO2 was reduced from 129 +/- 3 to 25 +/- 1 mm Hg, the diameter of cerebral arterioles increased by 66 +/- 9% (P < .05). Glibenclamide inhibited dilatation of pial arterioles during hypoxia by 46 +/- 5% (P < .05). In contrast, vasodilatation in response to sodium nitroprusside was not altered by glibenclamide. Topical application of adenosine (10(-4) mol/L) increased arteriolar diameter by 21 +/- 4%. Glibenclamide did not affect adenosine-induced vasodilatation. These findings suggest that dilatation of cerebral arterioles in response to hypoxia is mediated, in part, by activation of ATP-sensitive K+ channels.